2024 — ICLC

Characterizing the genomic landscape through the lens of FOLR1 status in low and high grade serous ovarian carcinoma
DIRAS3 induces autophagy and enhances sensitivity to anti-autophagic therapy in KRAS-driven pancreatic and ovarian carcinomas

3. Folate receptor alpha expression in low-grade serous ovarian cancer: Exploring new therapeutic possibilities

4. GOG-3097/ENGOT-ov81/GTG-UK/RAMP 301: a phase 3, randomized trial evaluating avutometinib plus defactinib compared with investigator's choice of treatment in patients with recurrent low grade serous ovarian cancer

5. High-throughput drug screening identifies novel therapeutics for Low Grade Serous Ovarian Carcinoma

6. High throughput screening identifies dasatinib as synergistic with trametinib in low grade serous ovarian carcinoma

7. Molecular Surrogate Subtypes of Ovarian and Peritoneal Low-grade Serous Carcinoma

8. Ovarian carcinosarcoma is highly aggressive compared to other ovarian cancer histotypes

9. Redefining the standard of care for low-grade serous ovarian cancer

10. Primary Cytoreduction and Survival for Patients With Less-Common Epithelial Ovarian Cancer

11. The prognostic value of MEK pathway–associated estrogen receptor signaling activity for female cancers

12. The survival benefit associated with complete macroscopic resection in epithelial ovarian cancer is histotype specific

2023